384 related articles for article (PubMed ID: 27677054)
1. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
[TBL] [Abstract][Full Text] [Related]
2. Trends in survival of leukemia among children, adolescents, and young adults: A population-based study in Osaka, Japan.
Nakata K; Okawa S; Fuji S; Sato A; Morishima T; Tada Y; Inoue M; Hara J; Kawa K; Miyashiro I;
Cancer Sci; 2021 Mar; 112(3):1150-1160. PubMed ID: 33428808
[TBL] [Abstract][Full Text] [Related]
3. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data.
Karalexi MA; Georgakis MK; Dessypris N; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Bouka E; Dana H; Hatzipantelis E; Kourti M; Moschovi M; Polychronopoulou S; Stiakaki E; Pourtsidis A; Petridou ET
Hematol Oncol; 2017 Dec; 35(4):608-618. PubMed ID: 27641612
[TBL] [Abstract][Full Text] [Related]
4. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
[TBL] [Abstract][Full Text] [Related]
5. Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978: a population-based study.
Gatta G; Luksch R; Coleman MP; Corazziari I;
Eur J Cancer; 2001 Apr; 37(6):695-702. PubMed ID: 11311643
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
[TBL] [Abstract][Full Text] [Related]
9. Incidence, time trends and survival patterns of childhood pilocytic astrocytomas in Southern-Eastern Europe and SEER, US.
Georgakis MK; Karalexi MA; Kalogirou EI; Ryzhov A; Zborovskaya A; Dimitrova N; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Agius D; Florea M; Coza D; Bouka E; Bourgioti C; Dana H; Hatzipantelis E; Moschovi M; Papadopoulos S; Sfakianos G; Papakonstantinou E; Polychronopoulou S; Sgouros S; Stefanaki K; Stiakaki E; Strantzia K; Zountsas B; Pourtsidis A; Patsouris E; Petridou ET
J Neurooncol; 2017 Jan; 131(1):163-175. PubMed ID: 27743145
[TBL] [Abstract][Full Text] [Related]
10. Persisting inequalities in survival patterns of childhood neuroblastoma in Southern and Eastern Europe and the effect of socio-economic development compared with those of the US.
Panagopoulou P; Georgakis MK; Baka M; Moschovi M; Papadakis V; Polychronopoulou S; Kourti M; Hatzipantelis E; Stiakaki E; Dana H; Tragiannidis A; Bouka E; Antunes L; Bastos J; Coza D; Demetriou A; Agius D; Eser S; Gheorghiu R; Šekerija M; Trojanowski M; Žagar T; Zborovskaya A; Ryzhov A; Dessypris N; Morgenstern D; Petridou ET
Eur J Cancer; 2018 Jun; 96():44-53. PubMed ID: 29673989
[TBL] [Abstract][Full Text] [Related]
11. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
12. Trends in leukemia incidence and survival in the United States (1973-1998).
Xie Y; Davies SM; Xiang Y; Robison LL; Ross JA
Cancer; 2003 May; 97(9):2229-35. PubMed ID: 12712476
[TBL] [Abstract][Full Text] [Related]
13. Survival and mortality rates of Wilms tumour in Southern and Eastern European countries: Socioeconomic differentials compared with the United States of America.
Doganis D; Panagopoulou P; Tragiannidis A; Vichos T; Moschovi M; Polychronopoulou S; Rigatou E; Papakonstantinou E; Stiakaki E; Dana H; Bouka P; Antunes L; Bastos J; Coza D; Demetriou A; Agius D; Eser S; Ryzhov A; Sekerija M; Trojanowski M; Zagar T; Zborovskaya A; Perisic SZ; Strantzia K; Dessypris N; Psaltopoulou T; Petridou ET
Eur J Cancer; 2018 Sep; 101():38-46. PubMed ID: 30014973
[TBL] [Abstract][Full Text] [Related]
14. Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia.
Millot F; Maledon N; Guilhot J; Güneş AM; Kalwak K; Suttorp M
Eur J Cancer; 2019 Jul; 115():17-23. PubMed ID: 31082688
[TBL] [Abstract][Full Text] [Related]
15. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
17. Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
Wu J; Chen Y; Hageman L; Francisco L; Ness EC; Parman M; Kung M; Watson JA; Weisdorf DJ; Snyder DS; McGlave PB; Forman SJ; Arora M; Armenian SH; Bhatia R; Bhatia S
Cancer; 2019 Nov; 125(22):4033-4042. PubMed ID: 31412155
[TBL] [Abstract][Full Text] [Related]
18. Value of survival gains in chronic myeloid leukemia.
Yin W; Penrod JR; Maclean R; Lakdawalla DN; Philipson T
Am J Manag Care; 2012 Nov; 18(11 Suppl):S257-64. PubMed ID: 23327457
[TBL] [Abstract][Full Text] [Related]
19. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
Liu YL; Wang XN; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
[TBL] [Abstract][Full Text] [Related]
20. Variation in survival of European children with acute lymphoblastic leukaemia, diagnosed in 1978--1992: the EUROCARE study.
Coebergh JW; Pastore G; Gatta G; Corazziari I; Kamps W;
Eur J Cancer; 2001 Apr; 37(6):687-94. PubMed ID: 11311642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
